Cell Therapy

The shift by Cellectis to prioritize APOC3 and PCSK9 programs illustrates a broader movement toward genomic modulation for long-lasting treatment of chronic illnesses. This strategic pivot marks a departure from the industry’s early fixation on ultra-rare genetic disorders, signaling a newfound

High-abundance proteins like albumin often mask rare signaling molecules, requiring a sophisticated depletion step to reveal the true regenerative potential of blood. This analytical challenge has long obscured the precise molecular mechanisms of platelet-rich plasma (PRP), a therapeutic

Unlike the single-infusion protocol of CAR T-cells, the repeated administration of bispecific antibodies may prevent the immune system from achieving full recovery. This observation has become central to oncological discussions in 2026 as these advanced immunotherapies dominate the treatment

Mapping the adult human intestine through spatial atlases is essential for bridging the biological gap between mouse models and human clinical applications. The human intestine remains one of the most biologically active environments in the body, defined by a relentless and necessary cycle of

Innovations in biomedical engineering at CU Boulder involve layering polymers to support the growth of essential cells for long-term vessel health. Cardiovascular diseases remain a critical global threat, claiming approximately 20 million lives annually and necessitating advanced surgical

By inducing the lysis of malignant cells, oncolytic viruses release a broad spectrum of neoantigens that can prime a patient’s native immune system through a process called epitope spreading. This mechanism represents a significant shift from the current clinical standard of single-target Chimeric